Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).

[1]  P. Chłosta,et al.  Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms , 2021 .

[2]  M. Stölzel,et al.  An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron‐Induced Cardiovascular Effects , 2017, Journal of clinical pharmacology.

[3]  Y. Homma,et al.  Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia , 2017, International journal of urology : official journal of the Japanese Urological Association.

[4]  M. Oelke,et al.  Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies , 2017, Therapeutic advances in urology.

[5]  C. Chapple,et al.  Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia , 2017, Expert review of clinical pharmacology.

[6]  A. Gomelsky,et al.  Treatment of Concomitant OAB and BPH , 2017, Current Urology Reports.

[7]  H. Kakizaki,et al.  Urodynamic Efficacy and Safety of Mirabegron Add‐on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder , 2016, Lower urinary tract symptoms.

[8]  Kyu-Sung Lee,et al.  Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia , 2015, Neurourology and urodynamics.

[9]  N. Masumori,et al.  A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. , 2015, The Journal of urology.

[10]  Y. Homma,et al.  Phase III, randomised, double‐blind, placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder , 2014, BJU international.

[11]  L. Cardozo,et al.  Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability , 2014, Neurourology and urodynamics.

[12]  M. Speakman,et al.  Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. , 2013, European urology.

[13]  Satoru Takahashi,et al.  Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study. , 2013, Urology.

[14]  M. Stölzel,et al.  A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. , 2013, Urology.

[15]  V. Nitti,et al.  Results of a randomized phase III trial of mirabegron in patients with overactive bladder. , 2013, The Journal of urology.

[16]  S. Kaplan,et al.  Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. , 2013, European urology.

[17]  G. Amarenco,et al.  Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. , 2013, European urology.

[18]  T. Tammela,et al.  [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe]. , 2012, Urologiia.

[19]  Y. Homma,et al.  Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. , 2011, Urology.

[20]  O. Yamaguchi,et al.  Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha‐blocker Combined with Anticholinergics , 2011, Lower urinary tract symptoms.

[21]  S. Kaplan,et al.  Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. , 2009, The Journal of urology.

[22]  P. Glue,et al.  Bmc Medical Research Methodology Open Access a Meta-analysis of the Placebo Response in Antimuscarinic Drug Trials for Overactive Bladder , 2022 .

[23]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[24]  G. Webster,et al.  Bladder diary volume per void measurements in detrusor overactivity. , 2006, The Journal of urology.

[25]  C. Roehrborn,et al.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. , 2006, JAMA.

[26]  Y. Homma,et al.  Silodosin, a new α1A‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese men , 2006, BJU international.

[27]  I. Hussain,et al.  Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. , 2006, Urology.

[28]  P. Meffan,et al.  Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder , 2004, BJU international.

[29]  C. Chapple.  MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER , 2000, Urology.

[30]  S. Radomski,et al.  Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive Bladder , 1999, International Urogynecology Journal.

[31]  A. Tewari,et al.  A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. , 1998, The Journal of urology.

[32]  H. Lepor.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.

[33]  P. Abrams,et al.  Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH) , 1995 .

[34]  P. Abrams,et al.  Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. , 1995, British journal of urology.